PE20040104A1 - Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco - Google Patents
Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmacoInfo
- Publication number
- PE20040104A1 PE20040104A1 PE2003000682A PE2003000682A PE20040104A1 PE 20040104 A1 PE20040104 A1 PE 20040104A1 PE 2003000682 A PE2003000682 A PE 2003000682A PE 2003000682 A PE2003000682 A PE 2003000682A PE 20040104 A1 PE20040104 A1 PE 20040104A1
- Authority
- PE
- Peru
- Prior art keywords
- weight
- potency
- sodium
- propharmac
- active ingredient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
QUE COMPRENDE: 1)UN NUCLEO DE COMPRIMIDO O RELLENO DE CAPSULAS, QUE A SU VEZ COMPRENDE: a)COMO INGREDIENTE ACTIVO 0,3% A 14%, EN PESO, DE (-)-CIS-6-FENIL-5-[4-(2-PIRROLIDIN-1-IL-ETOXI)FENIL]-5,6,7,8-TETRAHIDRONAFTALEN-2-OL; b)UN PROFARMACO DE (a) O UNA SAL, HIDRATO O SOLVATO FARMACEUTICAMENTE ACEPTABLE DEL COMPUESTO O DEL PROFARMACO; 2)3%, EN PESO, DE UN DISGREGANTE, SELECCIONADO DE: GLICOLATO SODICO DE ALMIDON, CARBOXIMETIL-CELULOSA SODICA, POLACRILINA POTASICA, CROSCARMELOSA SODICA, ENTRE OTROS; 3)0,5%, EN PESO, DE UN DESLIZANTE, SELECCIONADO DE DIOXIDO DE SILICIO, TALCO Y ALMIDON DE MAIZ; 4)1%,EN PESO DE UN LUBRICANTE, SELECCIONADO DE ESTEARATO DE CALCIO, MONOESTEARATO DE GLICERILO, PALMITOESTEARATO, ESTEARATO DE MAGNESIO, ENTRE OTROS; Y, 5)81% A 95%, EN PESO, APROXIMADAMENTE DE UN DILUYENTE/CARGA, SELECCIONADO DE: LACTOSA, MANITOL, XILITOL, DEXTROSA, SACAROSA, SORBITOL, CELULOSA MICROCRISTALINA, ENTRE OTROS. LA COMPOSICION DESCRITA TIENEN UNA DISTRIBUCION Y POTENCIA DE LASOFOXIFENO UNIFORME Y UTILIZA EL DIOXIDO DE SILICIO PARA REDUCIR LA PERDIDA DE INGREDIENTE ACTIVO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39509002P | 2002-07-10 | 2002-07-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20040104A1 true PE20040104A1 (es) | 2004-02-27 |
Family
ID=30115812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2003000682A PE20040104A1 (es) | 2002-07-10 | 2003-07-07 | Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US20040057992A1 (es) |
| EP (1) | EP1534248B1 (es) |
| JP (2) | JP4446446B2 (es) |
| KR (1) | KR100782693B1 (es) |
| CN (1) | CN100344278C (es) |
| AP (1) | AP2005003201A0 (es) |
| AR (1) | AR040434A1 (es) |
| AT (1) | ATE550017T1 (es) |
| AU (1) | AU2003247017B2 (es) |
| BR (1) | BR0312563A (es) |
| CA (1) | CA2489407C (es) |
| CY (1) | CY1112892T1 (es) |
| DK (1) | DK1534248T3 (es) |
| EA (1) | EA007268B1 (es) |
| EC (1) | ECSP055528A (es) |
| ES (1) | ES2395123T3 (es) |
| HK (1) | HK1077747A1 (es) |
| HN (1) | HN2003000206A (es) |
| HR (1) | HRP20041196A2 (es) |
| IL (2) | IL165746A0 (es) |
| IS (1) | IS7594A (es) |
| MA (1) | MA27318A1 (es) |
| MX (1) | MXPA05000394A (es) |
| NO (1) | NO20050018L (es) |
| NZ (1) | NZ537278A (es) |
| OA (1) | OA12883A (es) |
| PA (1) | PA8576201A1 (es) |
| PE (1) | PE20040104A1 (es) |
| PL (1) | PL374913A1 (es) |
| PT (1) | PT1534248E (es) |
| SI (1) | SI1534248T1 (es) |
| TN (1) | TNSN05006A1 (es) |
| TW (1) | TW200406222A (es) |
| UY (1) | UY27886A1 (es) |
| WO (1) | WO2004006895A1 (es) |
| ZA (1) | ZA200410196B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8576201A1 (es) * | 2002-07-10 | 2004-05-26 | Pfizer Prod Inc | Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco |
| US20040253305A1 (en) * | 2003-06-12 | 2004-12-16 | Luner Paul E. | Pharmaceutical compositions of atorvastatin |
| US20050271717A1 (en) * | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| EP1871359A1 (en) * | 2005-04-07 | 2008-01-02 | Miso Sabovic | Delaying the ageing process and disorders caused by ageing |
| WO2006118137A1 (ja) * | 2005-04-26 | 2006-11-09 | Dainippon Sumitomo Pharma Co., Ltd. | ビグアナイド系薬物を含有する粒状製剤 |
| GB0516604D0 (en) * | 2005-08-12 | 2005-09-21 | Sandoz Ag | Rapidly dispersing/disintegrating compositions |
| EP3173084B1 (en) | 2005-11-11 | 2019-10-23 | Boehringer Ingelheim International GmbH | Quinazoline derivatives for the treatment of cancer diseases |
| LT2487166T (lt) | 2007-02-23 | 2016-11-10 | Gilead Sciences, Inc. | Terapinių agentų farmakokinetinių savybių moduliatoriai |
| CA2835910C (en) * | 2007-04-25 | 2016-06-28 | Warner Chilcott Company, Llc | Improved vitamin d content uniformity in pharmaceutical dosage forms |
| US20100055180A1 (en) * | 2007-10-10 | 2010-03-04 | Mallinckrodt Baker, Inc. | Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof |
| CN101820863A (zh) * | 2007-10-10 | 2010-09-01 | 马林克罗特贝克公司 | 直接可压制的高功能性颗粒状微晶纤维素基赋形剂、其制备方法和用途 |
| WO2009135067A1 (en) * | 2008-05-01 | 2009-11-05 | Wyeth | Pharmaceutical polish formulations |
| SG190618A1 (en) * | 2008-05-02 | 2013-06-28 | Gilead Sciences Inc | The use of solid carrier particles to improve the processability of a pharmaceutical agent |
| US9545381B2 (en) * | 2009-07-06 | 2017-01-17 | Boehringer Ingelheim International Gmbh | Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
| RU2661402C2 (ru) * | 2011-10-17 | 2018-07-16 | Лексикон Фармасьютикалз, Инк. | Твердые дозированные формы (s)-этил 2-амино-3-(4-(2-амино-6((r)-1-(4-хлор-2-(3-метил-1н-пиразол-1-ил)фенил)-2,2,2-трифторэтокси)пиримидин-4-ил)фенил)пропаноата |
| DK2851075T3 (da) | 2012-05-14 | 2022-01-31 | Shionogi & Co | Præparat, der indeholder 6,7-umættet -7-carbamoylmorphinanderivat |
| PL3043778T3 (pl) * | 2013-09-13 | 2018-04-30 | Bayer Pharma Aktiengesellschaft | Kompozycje farmaceutyczne zawierające refametinib |
| RU2539375C1 (ru) * | 2013-11-07 | 2015-01-20 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Фармацевтическая композиция в форме таблетки и способ ее получения |
| US9242965B2 (en) | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
| CN103830196A (zh) * | 2014-03-14 | 2014-06-04 | 王志刚 | 一种酒石酸拉索昔芬分散片及其制备方法 |
| TWI535784B (zh) | 2014-08-26 | 2016-06-01 | 財團法人工業技術研究院 | 剪切增稠配方、及包含其之複合材料 |
| CN105434444B (zh) * | 2014-09-29 | 2021-02-05 | 上海奥奇医药科技有限公司 | 一种A-失碳-5α雄甾烷化合物的口服制剂 |
| US20190183850A1 (en) * | 2016-07-25 | 2019-06-20 | Canopy Growth Corporation | New cannabis tablet formulations and compositions and methods of making the same |
| JP6892151B2 (ja) | 2016-10-11 | 2021-06-23 | デューク ユニバーシティ | Ｅｒ＋乳がんのラソフォキシフェン処置 |
| EP3773524A4 (en) | 2018-04-10 | 2021-12-22 | Duke University | TREATMENT OF BREAST CANCER WITH LASOFOXIFEN |
| GB202116903D0 (en) | 2021-11-18 | 2022-01-05 | Sermonix Pharmaceuticals Inc | Lasofoxifene treatment of aromatase-resistant er+ cancer |
| CN114288258A (zh) * | 2022-02-18 | 2022-04-08 | 山东新时代药业有限公司 | 一种单硝酸异山梨酯片及其制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4182A (en) * | 1845-09-09 | Island | ||
| US4880636A (en) * | 1988-05-13 | 1989-11-14 | Franz Robert M | Film coated tablet of ranitidine HCl |
| US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
| UA51676C2 (uk) * | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція |
| TW442286B (en) * | 1996-02-28 | 2001-06-23 | Pfizer | New therapeutic uses of estrogen agonists |
| US6372457B1 (en) | 1997-01-14 | 2002-04-16 | Arkion Life Sciences Llc | Process and materials for production of glucosamine |
| KR200161927Y1 (ko) * | 1997-08-26 | 1999-12-01 | 윤종용 | 냉장고 |
| YU26700A (sh) * | 1999-05-24 | 2002-06-19 | Pfizer Products Inc. | Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin |
| US6436977B1 (en) * | 1999-09-29 | 2002-08-20 | Pfizer Inc. | Dosing regimens for lasofoxifene |
| US6419956B1 (en) * | 1999-12-30 | 2002-07-16 | Ancile Pharmaceuticals | Odor-masking coating for a pharmaceutical preparation |
| EP1145719A3 (en) * | 2000-03-10 | 2001-11-14 | Pfizer Products Inc. | Use a ferrous salt for inhibiting oxidative degradation of pharmaceutical formulations |
| AR029538A1 (es) * | 2000-07-06 | 2003-07-02 | Wyeth Corp | Composiciones farmaceuticas de agentes estrogenicos |
| OA12596A (en) * | 2001-05-01 | 2006-06-08 | Pfizer Prod Inc | Method for manufacturing a low dose pharmaceuticalcomposition. |
| PA8576201A1 (es) * | 2002-07-10 | 2004-05-26 | Pfizer Prod Inc | Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco |
-
2003
- 2003-06-23 PA PA20038576201A patent/PA8576201A1/es unknown
- 2003-06-30 KR KR1020057000369A patent/KR100782693B1/ko active IP Right Grant
- 2003-06-30 PT PT03764059T patent/PT1534248E/pt unknown
- 2003-06-30 AT AT03764059T patent/ATE550017T1/de active
- 2003-06-30 BR BR0312563-7A patent/BR0312563A/pt not_active IP Right Cessation
- 2003-06-30 MX MXPA05000394A patent/MXPA05000394A/es active IP Right Grant
- 2003-06-30 EP EP03764059A patent/EP1534248B1/en not_active Expired - Lifetime
- 2003-06-30 PL PL03374913A patent/PL374913A1/xx not_active Application Discontinuation
- 2003-06-30 WO PCT/IB2003/003074 patent/WO2004006895A1/en not_active Application Discontinuation
- 2003-06-30 OA OA1200500007A patent/OA12883A/en unknown
- 2003-06-30 IL IL16574603A patent/IL165746A0/xx unknown
- 2003-06-30 JP JP2004521001A patent/JP4446446B2/ja not_active Expired - Fee Related
- 2003-06-30 NZ NZ537278A patent/NZ537278A/en unknown
- 2003-06-30 DK DK03764059.6T patent/DK1534248T3/da active
- 2003-06-30 EA EA200401583A patent/EA007268B1/ru not_active IP Right Cessation
- 2003-06-30 ES ES03764059T patent/ES2395123T3/es not_active Expired - Lifetime
- 2003-06-30 CA CA002489407A patent/CA2489407C/en not_active Expired - Fee Related
- 2003-06-30 AP AP2005003201A patent/AP2005003201A0/xx unknown
- 2003-06-30 SI SI200332150T patent/SI1534248T1/sl unknown
- 2003-06-30 AU AU2003247017A patent/AU2003247017B2/en not_active Ceased
- 2003-06-30 CN CNB038162881A patent/CN100344278C/zh not_active Expired - Fee Related
- 2003-07-01 US US10/612,679 patent/US20040057992A1/en not_active Abandoned
- 2003-07-04 TW TW092118389A patent/TW200406222A/zh unknown
- 2003-07-07 PE PE2003000682A patent/PE20040104A1/es not_active Application Discontinuation
- 2003-07-07 HN HN2003000206A patent/HN2003000206A/es unknown
- 2003-07-08 UY UY27886A patent/UY27886A1/es not_active Application Discontinuation
- 2003-07-08 AR AR20030102454A patent/AR040434A1/es not_active Application Discontinuation
-
2004
- 2004-12-13 IS IS7594A patent/IS7594A/is unknown
- 2004-12-13 IL IL165746A patent/IL165746A/en active IP Right Grant
- 2004-12-17 HR HR20041196A patent/HRP20041196A2/hr not_active Application Discontinuation
- 2004-12-17 ZA ZA200410196A patent/ZA200410196B/en unknown
-
2005
- 2005-01-03 NO NO20050018A patent/NO20050018L/no not_active Application Discontinuation
- 2005-01-10 EC EC2005005528A patent/ECSP055528A/es unknown
- 2005-01-10 MA MA28036A patent/MA27318A1/fr unknown
- 2005-01-10 TN TNP2005000006A patent/TNSN05006A1/fr unknown
- 2005-11-04 HK HK05109850A patent/HK1077747A1/xx not_active IP Right Cessation
-
2006
- 2006-11-09 JP JP2006303440A patent/JP2007031451A/ja active Pending
- 2006-12-22 US US11/615,511 patent/US7553500B2/en not_active Expired - Fee Related
-
2012
- 2012-06-06 CY CY20121100504T patent/CY1112892T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20040104A1 (es) | Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco | |
| AR072755A2 (es) | Comprimido de carga de droga alta del compuesto 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida | |
| AR049000A1 (es) | Formulacion para compresion directa y proceso para la preparacion de una tableta directamente comprimida | |
| ECSP055733A (es) | Tabletas dispersables de deferacirox | |
| ES2240416T3 (es) | Utilizacion de un antagonista de los receptores de los canabinoides centrales para la preparacion de medicamentos utiles para facilitar la interrupcion del consumo de tabaco. | |
| PE20120654A1 (es) | Formulaciones de 4-amino-2-(2,6-dioxopiperidin-1,3-il) isoindolin-1,3-diona | |
| PA8629501A1 (es) | Tabletas dispersables que comprenden un derivado de acido benzoico | |
| NZ600231A (en) | Pharmaceutical compositions comprising sigma receptor ligands | |
| JP2010047612A5 (es) | ||
| NO20062004L (no) | Forlenget frigjoring farmasoytiske blandinger omfattene aplindor og derivater derav | |
| RS53690B1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING LEVETIRACETAM AND THE PROCESS FOR THEIR PREPARATION | |
| JP2018507200A5 (es) | ||
| UY28132A1 (es) | Derivados de pirrolopirimidina | |
| TW200714583A (en) | Substituted gamma lactams as therapeutic agents | |
| NO20072978L (no) | Nye betuinderivater, preparat derav og anvendelse derav | |
| NO20062713L (no) | 2,6 bisheteroaryl-4-aminopyrimidiner som adenosin reseptor antagonister | |
| NO20090141L (no) | Stabiliserte, farmasøytiske preparater som omfatter fesoterodin | |
| TW200736223A (en) | N-(pyridin-2-yl)-sulfonamide derivatives | |
| MX2007004769A (es) | Derivado de pirimidina condensado con un anillo no aromatico. | |
| NO20076418L (no) | Heterocyclic compounds as agonists for the thyroid receptor | |
| CY1109624T1 (el) | Υποκατεστημενα παραγωγα θειοφαινιου ως ανταγωνιστες υποδοχεα γλυκογονου, παρασκευη και θεραπευτικες χρησεις | |
| DK1675591T3 (da) | Farmaceutisk sammensætning omfattende en monoamin-neurotransmitter-genoptagelseshæmmer og en acetylcholinesterase-hæmmer | |
| KR102375262B9 (ko) | Glp-1 유사체, 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 미립구를 포함하는 약학적 조성물 | |
| PE20160550A1 (es) | Formulaciones de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona | |
| AR040248A1 (es) | Farmaco para el tratamiento de la vejiga hiperactiva |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |